Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Debt: 2020-2023

Historic Total Debt for Mirum Pharmaceuticals (MIRM) over the last 2 years, with Mar 2023 value amounting to $1.1 million.

  • Mirum Pharmaceuticals' Total Debt fell 45.39% to $1.1 million in Q1 2023 from the same period last year, while for Mar 2023 it was $1.1 million, marking a year-over-year decrease of 45.39%. This contributed to the annual value of $1.1 million for FY2022, which is 45.39% down from last year.
  • As of Q1 2023, Mirum Pharmaceuticals' Total Debt stood at $1.1 million, which was down 0.00% from $1.1 million recorded in Q4 2022.
  • Mirum Pharmaceuticals' 5-year Total Debt high stood at $2.2 million for Q2 2021, and its period low was $847,000 during Q3 2021.
  • In the last 3 years, Mirum Pharmaceuticals' Total Debt had a median value of $1.8 million in 2022 and averaged $1.5 million.
  • Examining YoY changes over the last 5 years, Mirum Pharmaceuticals' Total Debt showed a top increase of 114.62% in 2022 and a maximum decrease of 45.39% in 2022.
  • Over the past 4 years, Mirum Pharmaceuticals' Total Debt (Quarterly) stood at $1.3 million in 2020, then soared by 57.91% to $2.0 million in 2021, then crashed by 45.39% to $1.1 million in 2022, then slumped by 45.39% to $1.1 million in 2023.
  • Its Total Debt stands at $1.1 million for Q1 2023, versus $1.1 million for Q4 2022 and $1.8 million for Q3 2022.